Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Foghorn Therapeutics (FHTX) Assets Average (2020 - 2025)

Foghorn Therapeutics has reported Assets Average over the past 6 years, most recently at $201.5 million for Q4 2025.

  • Quarterly results put Assets Average at $201.5 million for Q4 2025, down 31.96% from a year ago — trailing twelve months through Dec 2025 was $201.5 million (down 31.96% YoY), and the annual figure for FY2025 was $241.0 million, down 15.41%.
  • Assets Average for Q4 2025 was $201.5 million at Foghorn Therapeutics, down from $215.6 million in the prior quarter.
  • Over the last five years, Assets Average for FHTX hit a ceiling of $504.0 million in Q1 2022 and a floor of $197.3 million in Q3 2021.
  • Median Assets Average over the past 5 years was $297.9 million (2023), compared with a mean of $316.6 million.
  • Biggest five-year swings in Assets Average: soared 125.76% in 2022 and later tumbled 32.3% in 2025.
  • Foghorn Therapeutics' Assets Average stood at $352.9 million in 2021, then rose by 18.84% to $419.4 million in 2022, then fell by 28.55% to $299.7 million in 2023, then decreased by 1.17% to $296.2 million in 2024, then plummeted by 31.96% to $201.5 million in 2025.
  • The last three reported values for Assets Average were $201.5 million (Q4 2025), $215.6 million (Q3 2025), and $242.5 million (Q2 2025) per Business Quant data.